Botanical species · safety record

Aesculus hippocastanum

The EFSA Compendium of Botanicals holds 9 constituent measurements, 3 adverse-effect records and 1 genotoxicity assay for Aesculus hippocastanum. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Aesculus hippocastanum L.

9Constituent measurements

4Safety records

7Cited sources

339Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 339 licensed products naming Aesculus hippocastanum as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Dry
Extract Type TBA
Fresh
decoction
solid

Source material stated

Buds
Buds and twigs
Cortex
Crushed dried kernels
Flower
Flower buds
Flowers
Flowers and buds

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Coumarins	Seed	Solvent extraction	—	Unspecified	Resolve DOI
Aescin	Seed	Solvent extraction	≤ 17.1 Percent	Colorimetry, Spectroscopy (Spectrometry) and Photometry	No resolvable identifier
Aescin	Seed	Solvent extraction	≥ 11.1 Percent	Colorimetry, Spectroscopy (Spectrometry) and Photometry	No resolvable identifier
Aescin	Live plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Coumarins	Bark	Solvent extraction	—	—	No resolvable identifier
Coumarins	Leaves	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Coumarins	Bud	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Coumarins	Fruit unspecified	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Saponins	Seed	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Nephrotoxicity	Urogenital: kidneys	Seed	Solvent extraction	—	Not reported	Resolve DOI
None	—	—	—	Rat (as animal)	Acute toxicity	No resolvable identifier
Pulmonary and cardiac	Neurologic: central nervous system	Seed	Fresh	Human (as organism)	Case report	No resolvable identifier

Genotoxicity testing

Outcomes of genotoxicity assays as recorded in the source. A negative assay is a result under those test conditions, not a clearance.

Outcome	Endpoint	Test	Tested organism	Metabolic activation	Source
Positive	—	bacterial reverse mutation assay	Salmonella typhimurium (as organism)	Without	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Panigati, D. Pharmacology of escin, a saponin from Aesculus hippocastanum L. Part III: Pharmacokinetics and toxicology. Bollettino chimico farmaceutico, 1992, p. 320-321.
Luyckx, V.A. Nephrotoxicity of Alternative Medicine Practice. Advances in chronic kidney disease, 2012, vol. 19, no. 3, p. 129-141. DOI
Felipe, M.B.M.C., de Carvalho, F.M., F�lix-Silva, J., Fernandes-Pedrosa, M.F., Scortecci, K.C., Agnez-Lima, L.F., Batistuzzo de Medeiros, S.R. Evaluation of genotoxic and antioxidant activity of an Aesculus hippocastanum L. (Sapindaceae) phytotherapeutic agent. Biomedicine and preventive nutrition, 2013, vol. 3, no. 3, p. 261-266. DOI
Corcilius, F. Paper chromatographic investigations of hydroxycoumarins and flavones from horse chestnut (Aesculus hippocastanum). Planta medica, 1955, p. 55-61.
Felipe, M.B.M.C., de Carvalho, F.M., Félix-Silva, J., Fernandes-Pedrosa, M.F., Scortecci, K.C., Agnez-Lima, L.F., Batistuzzo de Medeiros, S.R. Evaluation of genotoxic and antioxidant activity of an Aesculus hippocastanum L. (Sapindaceae) phytotherapeutic agent. Biomedicine and preventive nutrition, 2013, vol. 3, no. 3, p. 261-266. DOI
Khudyakova, S. S., Bogoyavlenskii, A. P., Levandovskaya, S. V., Tustikbaeva, G. B., Tolmacheva, V. P., Makhmudova, N. R., Ermakova, O. S., Berezin, V. E. Obtaining saponins of low toxicity from plants of Aesculus hippocastanum. Izvestiya natsional'noi akademii nauk respubliki kazakhstan, seriya biologicheskaya i meditsinskaya, 2004, p. 66-71.
Hammerstein, F., Kaiser, F. Quantitative direct fluorometric determination of extracts of medicinal plants on thin-layer-chromatograms. Planta medica, 1972, p. 5-15.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature